Trial Profile
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Prednisone
- Indications Psoriatic arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Amgen; Celgene Corporation
- 12 Jun 2012 Results published in Arthritis and Rheumatism.
- 05 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 May 2011 Patient-reported outcomes results presented at the 12th Annual Congress of the European League Against Rheumatism.